Eli Lilly and Company, together with partner Innovent Biologics, announced today that China’s National Medical Products Administration will review its application for IBI301, a proposed rituximab biosimilar referencing MabThera and Rituxan.
Eli Lilly and Company, together with partner Innovent Biologics, announced today that China’s National Medical Products Administration will review its application for IBI301, a proposed rituximab biosimilar referencing MabThera and Rituxan.
According to the partnership, the biosimilar has the opportunity to increase access for Chinese patients; despite a high unmet demand for effective cancer treatments, use of rituximab remains relatively low due to its high cost.
Li Wang, MD, PhD, senior vice president of Lilly China and head of Lilly China drug development and medical affairs, said of the submission in a statement, "The NDA of IBI301 represents another millstone of strategic cooperation between Lilly and Innovent. We hope that IBI301 can be approved soon in order to offer an affordable treatment option for lymphoma patients in China."
Last month, the partnership announced that 2 studies of the biosimilar had met their primary end points. The first, a single-dose study, assessed the pharmacokinetics, safety, tolerability, and immunogenicity of the biosimilar versus the reference drug in 181 patients with CD20-positive B-cell lymphoma. The drug makers reported that the study met its primary end point, area under the concentration—time curve from time zero to infinity, over a time frame of 91 days.
The second study, a phase 3 trial in 420 patients with diffuse large B-cell lymphoma who received either the biosimilar or the reference drug in combination with standard chemotherapy for 6 cycles as first-line treatment for newly diagnosed disease, met its primary end point of overall response rate over a time frame of 18 weeks.
If approved, Lilly and Innovent’s rituximab will join 1 other approved biosimilar rituximab product in the Chinese marketplace; in February 2019, China approved Henlius’ HLX01. Approval of this rituximab product was a milestone for the Chinese market, as it was not only the first rituximab biosimilar to be approved in the market, but also the first biosimilar to be cleared under the country’s biosimilar approval pathway.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Alvotech’s Stelara Biosimilar, Selarsdi, Receives FDA Approval
April 16th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.